CTGF is a therapeutic target for metastatic melanoma

Metastatic melanoma remains a devastating disease with a 5-year survival rate of less than five percent. Despite recent advances in targeted therapies for melanoma, only a small percentage of melanoma patients experience durable remissions. Therefore, it is critical to identify new therapies for the...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Finger, EC, Cheng, C-F, Williams, TR, Rankin, EB, Bedogni, B, Tachiki, L, Spong, S, Giaccia, AJ, Powell, MB
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3965577/
https://ncbi.nlm.nih.gov/pubmed/23435419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2013.47
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller